Your AI-Trained Oncology Knowledge Connection!
In October 2023, the FDA approved frontline toripalimab-tpzi plus cisplatin and gemcitabine for adult patients with metastatic or locally advanced nasopharyngeal carcinoma, as well as single-agent toripalimab for recurrent, unresectable, or metastatic disease that has progressed on or following prior chemotherapy.
In August 2022, the FDA granted approval to oral darolutamide in combination with docetaxel for the treatment of patients with metastatic hormone-sensitive prostate cancer.
In March 2022, the FDA granted approval to the targeted radioligand 177Lu-PSMA-617 for the treatment of patients with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer who have previously been treated with an androgen-receptor pathway inhibitor and taxane-based chemotherapy.
In November 2021, the FDA approved pafolacianine for use as an imaging drug for identifying lesions in patients with ovarian cancer during surgery.
